ENGENE HOLDINGS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.52 USD | -2.75% |
|
-8.62% | +57.31% |
| 04-22 | Wells Fargo Starts enGene Holdings With Overweight Rating, $30 Price Target | MT |
| 04-15 | Guggenheim Starts enGene Holdings With Buy Rating, $34 Price Target | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 640M 51.34B |
|---|---|---|---|---|---|
| Net income 2024 * | -54M -4.33B | Net income 2025 * | -71M -5.69B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 233M 18.64B | Net cash position 2025 * | 342M 27.39B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-11
x | P/E ratio 2025 * |
-9.93
x | Employees | 32 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.64% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.75% | ||
| 1 week | -8.62% | ||
| Current month | -8.68% | ||
| 1 month | -10.76% | ||
| 3 months | +82.64% | ||
| 6 months | +70.82% | ||
| Current year | +57.31% |
1 week
14.48
16.00
1 month
13.4916.67
Current year
7.1018.40
1 year
6.6947.17
3 years
6.6947.17
5 years
6.6947.17
10 years
6.6947.17
| Managers | Title | Age | Since |
|---|---|---|---|
Jason Hanson
CEO | Chief Executive Officer | 55 | 07/08/23 |
Anthony Cheung
FOU | Founder | 53 | 23/04/23 |
| President | 38 | 10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-17 |
Jason Hanson
CEO | Chief Executive Officer | 55 | 07/08/23 |
Gerry Brunk
BRD | Director/Board Member | 55 | 07/08/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/24 | 14.52 | -2.75% | 20,966 |
| 07/05/24 | 14.93 | -3.62% | 315,679 |
| 06/05/24 | 15.49 | -0.13% | 741,978 |
| 03/05/24 | 15.51 | +1.24% | 222,557 |
| 02/05/24 | 15.32 | -3.59% | 132,062 |
End-of-day quote Nasdaq, May 07, 2024
More quotes
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Companyâs proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Companyâs DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.
Calendar
15/05/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.52
USD
Average target price
34.4
USD
Spread / Average Target
+136.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +57.31% | 640M | |
| +22.56% | 46.71B | |
| -1.51% | 41.52B | |
| +48.83% | 41.8B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| -20.44% | 19.26B | |
| +26.45% | 11.98B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B |
- Stock Market
- Equities
- ENGN Stock
